Sanofi US announced that it has launched an authorized generic version of Eloxatin (oxaliplatin injection) through Winthrop US, the company’s generics division. Sanofi’s authorized generic version is the same formulation as the original drug, Eloxatin, for which the company holds the original patent. 

 

Eloxatin is a platinum-based drug used in combination with infusional 5-fluorouracil/leucovorin. This treatment is indicated for treatment of advanced colorectal cancer or as adjuvant treatment of stage III colon cancer in patients who have undergone complete resection of the primary tumor. The authorized generic version of Eloxatin will be available in the same sizes, 50 mg and 100 mg single-use vials. 

 

“We are committed to broadening access to our medicines and providing more affordable treatment options for patients,” said Charles Hugh-Jones, chief medical officer, North America, Sanofi. “The availability of an authorized generic version of Eloxatin is welcomed news for patients and physicians alike.”

 

According to the Centers for Disease Control and Prevention (CDC), “of cancers that affect both men and women, colorectal cancer is the second leading cancer killer in the United States.”

 

Winthrop US delivers affordable solutions to the healthcare community by transforming Sanofi’s branded products into authorized generics and is devoted to supplying high quality products to its customers with excellent service. 

 

Date: August 12, 2014

Source: Sanofi US